Kymera Therapeutics (KYMR) Projected to Post Quarterly Earnings on Thursday

Kymera Therapeutics (NASDAQ:KYMR) is anticipated to release its earnings data before the market opens on Thursday, February 27th. Analysts expect Kymera Therapeutics to post earnings of ($0.76) per share and revenue of $14.81 million for the quarter. Persons interested in registering for the company’s earnings conference call can do so using this link.

Kymera Therapeutics Price Performance

Shares of NASDAQ:KYMR opened at $35.31 on Tuesday. The company has a market capitalization of $2.29 billion, a P/E ratio of -15.09 and a beta of 2.18. Kymera Therapeutics has a 1-year low of $29.24 and a 1-year high of $53.27. The firm’s 50 day simple moving average is $39.61 and its two-hundred day simple moving average is $44.02.

Insider Buying and Selling at Kymera Therapeutics

In other news, insider Ellen Chiniara sold 3,129 shares of the business’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $41.75, for a total value of $130,635.75. Following the sale, the insider now directly owns 54,826 shares in the company, valued at $2,288,985.50. The trade was a 5.40 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 15.82% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on KYMR. BMO Capital Markets began coverage on shares of Kymera Therapeutics in a research note on Friday, December 6th. They set a “market perform” rating and a $55.00 target price on the stock. UBS Group lowered their target price on shares of Kymera Therapeutics from $80.00 to $74.00 and set a “buy” rating on the stock in a research note on Monday, November 4th. Wells Fargo & Company upgraded shares of Kymera Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their target price for the company from $38.00 to $57.00 in a research note on Monday, December 2nd. Stephens restated an “overweight” rating and set a $60.00 target price on shares of Kymera Therapeutics in a research note on Tuesday, January 21st. Finally, Morgan Stanley lifted their target price on shares of Kymera Therapeutics from $45.00 to $49.00 and gave the company an “equal weight” rating in a research note on Wednesday, November 6th. Three analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Kymera Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $55.64.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.